International Journal of Biological Sciences · 2020 · 18 citations · 46 references
Life SciencesMolecular BiologyOncologyEpigeneticsGene ExpressionMolecular OncologyApoptosis In CancerCancer EpigeneticsEpigenetic Regulation In CancerMicrorna BiologyMicrorna-mediated RegulationTumor Suppressor GenesAcute Myeloid Leukemia BiologyG1 Cell-cycle ArrestMicroarray AnalysisMicrorna EpigeneticsMicrorna In CancerMicrorna In Cell ProliferationMicrorna Regulation In CancerWilms Tumor 1
MicroRNAs (miRNAs) and N 6 -methyladenosine (m 6 A) are known to serve as key regulators of acute myeloid leukemia (AML). Our previous microarray analysis indicated miR-550-1 was significantly downregulated in AML. The specific biological roles of miR-550-1 and its indirect interactions and regulation of m 6 A in AML, however, remain poorly understood. At the present study, we found that miR-550-1 was significantly down-regulated in primary AML samples from human patients, likely owing to hypermethylation of the associated CpG islands. When miR-550-1 expression was induced, it impaired AML cell proliferation both in vitro and in vivo, thus suppressing tumor development. When ectopically expressed, miR-550-1 drove the G0/1 cell cycle phase arrest, differentiation, and apoptotic death of affected cells. We confirmed mechanistically that WW-domain containing transcription regulator-1 (WWTR1) gene was a downstream target of miR-550-1. Moreover, we also identified Wilms tumor 1-associated protein (WTAP), a vital component of the m 6 A methyltransferase complex, as a target of miR-550-1. These data indicated that miR-550-1 might mediate a decrease in m 6 A levels via targeting WTAP, which led to a further reduction in WWTR1 stability. Using gain-and loss-of-function approaches, we were able to determine that miR-550-1 disrupted the proliferation and tumorigenesis of AML cells at least in part via the direct targeting of WWTR1. Taken together, our results provide direct evidence that miR-550-1 acts as a tumor suppressor in the context of AML pathogenesis, suggesting that efforts to bolster miR-550-1 expression in AML patients may thus be a viable clinical strategy to improve patient outcomes.
46
Mammalian microRNAs predominantly act to decrease target mRNA levels
Huili Guo, Nicholas T. Ingolia, Jonathan S. Weissman et al. · Nature · 2010 · 3.9K citations · Full text
A Mammalian microRNA Expression Atlas Based on Small RNA Library Sequencing
Pablo Landgraf, Mirabela Rusu, Robert P. Sheridan et al. · Cell · 2007 · 3.7K citations · Full text
A microRNA polycistron as a potential human oncogene
Lin He, J. Michael Thomson, Michael T. Hemann et al. · Nature · 2005 · 3.5K citations
FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N 6 -Methyladenosine RNA Demethylase
Zejuan Li, Hengyou Weng, Rui Su et al. · Cancer Cell · 2016 · 1.6K citations
N6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells
Yang Wang, Yue Li, Julia I. Toth et al. · Nature Cell Biology · 2014 · 1.3K citations